Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence

Abstract

Anticoagulation with heparin and vitamin K antagonist has been the mainstay of prevention and treatment of venous thromboembolism (VTE) for many years. In recent years, novel oral anticoagulants such as dabigatran etexilate (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (a direct factor Xa inhibitor) have emerged for the prevention… (More)
DOI: 10.2147/DDDT.S51006

Topics

5 Figures and Tables

Cite this paper

@inproceedings{Zalpour2014ClinicalUO, title={Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence}, author={Ali Zalpour and Thein Hlaing Oo}, booktitle={Drug design, development and therapy}, year={2014} }